EichorEICHOR
Location: Huizhou Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Huizhou

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Phase 2 · Investigational Site Number : 1560003 · Sanofi · NCT06867094This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Huizhou Central People's Hospital · Pfizer · NCT06758401Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis
Phase N/A · Huizhou Central People's Hospital · Nanfang Hospital, Southern Medical University · NCT06307327EBUS-TTFB vs EBUS-TBNA for Diagnosing Inadequate Lymph Node Specimens Based on MOSE
NA · Huzhou Central Hospital · Shanghai Chest Hospital · NCT06913569Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Huizhou Central Peoples Hospital · Amgen · NCT07037433A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Phase 2 · Huizhou Central People's Hospital · Eli Lilly and Company · NCT07483099LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Phase 2 · Huizhou Central People's Hospital · Eli Lilly and Company · NCT07415044A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Phase 3 · Huizhou Central People's Hospital · argenx · NCT06544499Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Che
Phase 2 · The Central People's Hospital of Huizhou · Tianjin Medical University Cancer Institute and Hospital · NCT06141226Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
Phase 2 · Huizhou First Hospital · InSilico Medicine Hong Kong Limited · NCT07265570A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Sta
Phase 3 · Huizhou Central People's Hospital · Bristol-Myers Squibb · NCT06561386eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO
Phase 3 · GSK Investigational Site · GlaxoSmithKline · NCT07177339An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type
Phase 3 · Huizhou Central People's Hospital · Hoffmann-La Roche · NCT07351058An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ
Phase 3 · Investigational Site Number : 1560026 · Sanofi · NCT07184931A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
Phase 3 · Research Site · AstraZeneca · NCT06471257A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · DualityBio Inc. · NCT05150691Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-Hi
Phase 2 · Research Site · AstraZeneca · NCT06932263A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD
Phase 3 · Huizhou Central People's Hospital · Hoffmann-La Roche · NCT05878769Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontroll
Phase 3 · Research Site · AstraZeneca · NCT06750289ASPIrin in Reducing Events in Dialysis ( ASPIRED )
Phase 4 · Huizhou First People Hospital · Guangdong Provincial People's Hospital · NCT04381143Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Canc
Phase 1/Phase 2 · The Affiliated Huizhou Hospital, Guangzhou Medical Universit · Guangzhou Medical University · NCT06462092A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Phase 3 · Huizhou Central People's Hospital · Takeda · NCT05837897A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
Phase 3 · Investigator Site 08 · Waterstone Pharmaceutical (Wuhan) Co., LTD. · NCT07251309A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
Phase 2 · GSK Investigational Site · GlaxoSmithKline · NCT07201051Efficacy and Safety Evaluation of Absorbable and Moldable Skull Base Support Plates in Extended Endoscopic Endonasal Tra
Phase 2 · Huizhou Central People's Hospital · Nanfang Hospital, Southern Medical University · NCT07539792Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Phase 2 · The Affiliated Huizhou Hospital, Guangzhou Medical Universit · Guangzhou Medical University · NCT06296745A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Phase 2 · Huizhou Central People's Hospital · Eli Lilly and Company · NCT07483073Phase II Study of RC1416 Injection in COPD
Phase 2 · Huizhou Third People's Hospital · Nanjing RegeneCore Biotech Co., Ltd. · NCT07402551A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events i
Phase N/A · The Third Peoples Hospital of Huizhou · Amgen · NCT06295679
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.